TO ACESS LEVEL OF CA 19.9( CARBOHYDRATE ANTIGEN 19.9) & CA125 (CARBOHYDRATE ANTIGEN 125) IN PATIENTS OF CANCER ( OVARIAN, ENDOMETRIAL & PANCREATIC)

Farah Ahsan, Sonali Kukreti, Sumera Samreen
In: International Journal of Advanced Research · 2021 · vol. 9(01) , pp. 1133–1137 · doi:10.21474/ijar01/12401 · W3132966844
article OA: hybrid CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-15 ⓘ

Serum CA 19.9 and CA 125 levels were significantly higher in patients with ovarian cancer, pancreatic carcinoma, and endometriosis compared to controls, indicating elevated markers across these malignancies and benign conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-09 · read from full text ⓘ

This study evaluated the diagnostic utility of serum CA 19.9 and CA 125 levels in patients presenting with symptoms of ovarian, endometrial, or pancreatic cancer. The researchers analyzed samples from 100 randomly selected patients using electrochemiluminescent immunoassay to compare biomarker concentrations against control groups. Results indicated that malignant tumors were associated with significantly higher levels of both markers compared to controls, while elevated values also correlated with benign conditions like endometriosis. Specifically, high CA 19.9 levels were observed in pancreatic carcinoma cases, whereas moderate elevations appeared in females with endometriosis. Relevance to endometriosis: listed as one indication for CA 125 elevation, though the paper's main focus is distinguishing malignancies from benign conditions like endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Purpose: To investigate the diagnostic value of CA 19.9 & CA125 in patients of cancer. Methods: 100 randomly selected patients coming to Medicine & Gynae OPD with symptoms of cancer. Serum was taken and CA19.9 & CA 125 was analyzed by Electrochemiluminescent Immunoassay. Results: It showed serum levels of CA19.9 & CA125 of patient with malignant ovarian, endometriosis & pancreatic tumor significantly higher than the control group. Out of total 50 patients for CA19.9, 45 were females & 5 males. Out of 45 females, 14 females & 3 males have raised value. All 3 males have significantly raised value more than 500 U/ml & All 3 had pancreatic carcinoma. Out of 14 females those had value more than 1000 had features of malignancy whereas rest females of value more than 100 had features of endometriosis. For CA125 total of 50 patients were taken out of which only 10 patients had raised CA125 level. All were females and 60% had value more than cut off that was 35u/ml. Out of the 10 females who had raised CA125, 6 had carcinoma & metastasis & rest 4 had endometriosis.
Full text 1,812 characters · extracted from oa-html · 3 sections · click to expand

Abstract

Purpose: To investigate the diagnostic value of CA 19.9 & CA125 in patients of cancer.

Methods

100 randomly selected patients coming to Medicine & Gynae OPD with symptoms of cancer. Serum was taken and CA19.9 & CA 125 was analyzed by Electrochemiluminescent Immunoassay.

Results

It showed serum levels of CA19.9 & CA125 of patient with malignant ovarian, endometriosis & pancreatic tumor significantly higher than the control group. Out of total 50 patients for CA19.9, 45 were females & 5 males. Out of 45 females, 14 females & 3 males have raised value. All 3 males have significantly raised value more than 500 U/ml & All 3 had pancreatic carcinoma. Out of 14 females those had value more than 1000 had features of malignancy whereas rest females of value more than 100 had features of endometriosis. For CA125 total of 50 patients were taken out of which only 10 patients had raised CA125 level. All were females and 60% had value more than cut off that was 35u/ml. Out of the 10 females who had raised CA125, 6 had carcinoma & metastasis & rest 4 had endometriosis. How to Cite This Article Farah Ahsan, Sonali Kukreti and Sumera Samreen (2021); TO ACESS LEVEL OF CA 19.9( CARBOHYDRATE ANTIGEN 19.9) & CA125 (CARBOHYDRATE ANTIGEN 125) IN PATIENTS OF CANCER ( OVARIAN, ENDOMETRIAL & PANCREATIC), International Journal of Advanced Research (IJAR), 9 (01), 1133-1137, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/12401

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK